Skip to main content
Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery 1/2019

07.04.2018 | Original Article

Xanthelasma Palpebrarum: More than Meets the Eye

verfasst von: Shailesh Khode, Soon Heng Terry Tan, En-Pei Amanda Tan, Sandeep Uppal

Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery | Sonderheft 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Xanthelasma palpebrarum (XP) is the most common form of cutaneous xanthomata, and is important aesthetically, because of its close relation to the eyes, as well as medically for its association with cardiovascular disease (CVD). To provide avant-garde review discussing the various aspects of XP, including its aetio-pathogenesis and various treatment modalities. A structured Pubmed and Medline were searched for relevant articles. The finding of recent research has strongly espoused the link between XP and CVD, and mechanisms have been suggested for its formation. The new technologies have led to a multitude of treatment options for XP. XP is a multi-faceted entity; other than simple treatment of the cosmetic aspect of the disease, one must be cognizant of its cardiovascular implications.
Literatur
1.
Zurück zum Zitat Bergman R (1994) The pathogenesis and clinical significance of xanthelasma palpebrarum. J Am Acad Dermatol 30(2):236–242PubMed Bergman R (1994) The pathogenesis and clinical significance of xanthelasma palpebrarum. J Am Acad Dermatol 30(2):236–242PubMed
2.
Zurück zum Zitat Domonkoa AN, Arnold HL Jr., Odom RB (1982) Andrews’ diseases of the skin: clinical dermatology, 7th edn. WB Saunders, Philadelphia, pp 658–660 Domonkoa AN, Arnold HL Jr., Odom RB (1982) Andrews’ diseases of the skin: clinical dermatology, 7th edn. WB Saunders, Philadelphia, pp 658–660
3.
Zurück zum Zitat Jónsson A, Sigfŭsson N (1976) Letter: significance of xanthelasma palpebrarum in the normal population. Lancet 1(7955):372PubMed Jónsson A, Sigfŭsson N (1976) Letter: significance of xanthelasma palpebrarum in the normal population. Lancet 1(7955):372PubMed
4.
Zurück zum Zitat Dequeker J, Muls E, Leenders K (2004) Xanthelasma and lipoma in Leonardo da Vinci’s Mona Lisa. Isr Med Assoc J 6(8):505–506PubMed Dequeker J, Muls E, Leenders K (2004) Xanthelasma and lipoma in Leonardo da Vinci’s Mona Lisa. Isr Med Assoc J 6(8):505–506PubMed
5.
6.
Zurück zum Zitat Sarkany RPE, Breathnach SM, Seymour CA et al (2004) Metabolic and nutritional diseases. In: Burns T, Breathnach S, Cox N et al (eds) Rook’s textbook of dermatology, vol 7. Blackwell, Oxford, p 57.1e57.124 Sarkany RPE, Breathnach SM, Seymour CA et al (2004) Metabolic and nutritional diseases. In: Burns T, Breathnach S, Cox N et al (eds) Rook’s textbook of dermatology, vol 7. Blackwell, Oxford, p 57.1e57.124
7.
Zurück zum Zitat Matsumoto M, Kunimitsu S, Wada K, Ikeda M, Keyama A, Kodama H (2007) Mast cell distribution, activation, and phenotype in xanthoma. J Am Acad Dermatol 56(6):1006–1012PubMed Matsumoto M, Kunimitsu S, Wada K, Ikeda M, Keyama A, Kodama H (2007) Mast cell distribution, activation, and phenotype in xanthoma. J Am Acad Dermatol 56(6):1006–1012PubMed
8.
Zurück zum Zitat Parker F, Odland GF (1968) Experimental xanthoma. A correlative biochemical, histologic, histochemical, and electron microscopic study. Am J Pathol 53(4):537–565PubMedPubMedCentral Parker F, Odland GF (1968) Experimental xanthoma. A correlative biochemical, histologic, histochemical, and electron microscopic study. Am J Pathol 53(4):537–565PubMedPubMedCentral
9.
Zurück zum Zitat Parker F, Peterson N, Odland GF (1966) A comparison of cholesterol-ester fatty acid patterns in the blood and in evolving xanthoma and atheroma during cholesterol-feeding of rabbits. J Invest Dermatol 47(3):253–259PubMed Parker F, Peterson N, Odland GF (1966) A comparison of cholesterol-ester fatty acid patterns in the blood and in evolving xanthoma and atheroma during cholesterol-feeding of rabbits. J Invest Dermatol 47(3):253–259PubMed
10.
Zurück zum Zitat Watanabe A, Yoshimura A, Wakasugi T et al (1981) Serum lipids, lipoprotein lipids and coronary heart disease in patients with xanthelasma palpebrarum. Atherosclerosis 38:283–290PubMed Watanabe A, Yoshimura A, Wakasugi T et al (1981) Serum lipids, lipoprotein lipids and coronary heart disease in patients with xanthelasma palpebrarum. Atherosclerosis 38:283–290PubMed
11.
Zurück zum Zitat Ribera M, Pinto X, Argimon JM et al (1995) Lipid metabolism and apolipoprotein-E phenotypes in patients with xanthelasma. Am J Med 99:485–490PubMed Ribera M, Pinto X, Argimon JM et al (1995) Lipid metabolism and apolipoprotein-E phenotypes in patients with xanthelasma. Am J Med 99:485–490PubMed
12.
Zurück zum Zitat Gómez JA, Gónzalez MJ, de Moragas JM, Serrat J, Gónzalez-Sastre F, Pérez M (1988) Apolipoprotein E phenotypes, lipoprotein composition, and xanthelasmas. Arch Dermatol 124(8):1230–1234PubMed Gómez JA, Gónzalez MJ, de Moragas JM, Serrat J, Gónzalez-Sastre F, Pérez M (1988) Apolipoprotein E phenotypes, lipoprotein composition, and xanthelasmas. Arch Dermatol 124(8):1230–1234PubMed
13.
Zurück zum Zitat Montgomery H, Osterberg A (1938) Xanthomatosis: correlation of clinical, histopathologic, and chemical studies of cutaneous xanthoma. Arch Dermatol 37:373–401 Montgomery H, Osterberg A (1938) Xanthomatosis: correlation of clinical, histopathologic, and chemical studies of cutaneous xanthoma. Arch Dermatol 37:373–401
14.
Zurück zum Zitat Vacca JB, Knight WA, Broun GO (1959) Clinical observations regarding xanthelasma. Ann Intern Med 51:1019–1031PubMed Vacca JB, Knight WA, Broun GO (1959) Clinical observations regarding xanthelasma. Ann Intern Med 51:1019–1031PubMed
15.
Zurück zum Zitat Epstein NN, Rosenmann RH, Gofman JW (1952) Serum lipoproteins and cholesterol metabolism in xanthelasma. Arch Dermatol 65:70–81 Epstein NN, Rosenmann RH, Gofman JW (1952) Serum lipoproteins and cholesterol metabolism in xanthelasma. Arch Dermatol 65:70–81
16.
Zurück zum Zitat Pedace JF, Winkelmann RK (1965) Xanthelasma palpebrarum. J Am Med Assoc 193:893–894 Pedace JF, Winkelmann RK (1965) Xanthelasma palpebrarum. J Am Med Assoc 193:893–894
17.
Zurück zum Zitat Bergman R (1998) Xanthelasma palpebrarum and risk of atherosclerosis. Int J Dermatol 37(5):343–345PubMed Bergman R (1998) Xanthelasma palpebrarum and risk of atherosclerosis. Int J Dermatol 37(5):343–345PubMed
18.
Zurück zum Zitat Bergman R, Kasif Y, Aviram M, Maor I, Ullman Y, Gdal-On M, Friedman-Birnbaum R (1996) Normolipidemic xanthelasma palpebrarum: lipid composition, cholesterol metabolism in monocyte-derived macrophages, and plasma lipid peroxidation. Acta Derm Venereol 76(2):107–110PubMed Bergman R, Kasif Y, Aviram M, Maor I, Ullman Y, Gdal-On M, Friedman-Birnbaum R (1996) Normolipidemic xanthelasma palpebrarum: lipid composition, cholesterol metabolism in monocyte-derived macrophages, and plasma lipid peroxidation. Acta Derm Venereol 76(2):107–110PubMed
19.
Zurück zum Zitat Douste-Blazy P, Marcel YL, Cohen L, Giroux JM, Davignon J (1982) Increased Frequency of Apo E-ND phenotype and hyperapobeta-lipoproteinemia in normolipidemic subjects with xanthelasmas of the eyelids. Ann Intern Med 96(2):164–169PubMed Douste-Blazy P, Marcel YL, Cohen L, Giroux JM, Davignon J (1982) Increased Frequency of Apo E-ND phenotype and hyperapobeta-lipoproteinemia in normolipidemic subjects with xanthelasmas of the eyelids. Ann Intern Med 96(2):164–169PubMed
20.
Zurück zum Zitat Greenland P, Abrams J, Aurigemma GP et al (2000) Prevention conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: non-invasive tests of atherosclerotic burden—Writing Group III. Circulation 101:E16e22 Greenland P, Abrams J, Aurigemma GP et al (2000) Prevention conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: non-invasive tests of atherosclerotic burden—Writing Group III. Circulation 101:E16e22
21.
Zurück zum Zitat Noël B (2007) Premature atherosclerosis in patients with xanthelasma. J Eur Acad Dermatol Venereol 21(9):1244–1248PubMed Noël B (2007) Premature atherosclerosis in patients with xanthelasma. J Eur Acad Dermatol Venereol 21(9):1244–1248PubMed
22.
Zurück zum Zitat Pandhi D, Gupta P, Singal A, Tondon A, Sharma S, Madhu SV (1038) Xanthelasma palpebrarum: a marker of premature atherosclerosis (risk of atherosclerosis in xanthelasma). Postgrad Med J 2012(88):198–204 Pandhi D, Gupta P, Singal A, Tondon A, Sharma S, Madhu SV (1038) Xanthelasma palpebrarum: a marker of premature atherosclerosis (risk of atherosclerosis in xanthelasma). Postgrad Med J 2012(88):198–204
23.
Zurück zum Zitat Akyuz AR, Turan T, Erkus ME, Gurbak KS et al (2016) Xanthelasma palpebrarum associated with increased cardio-ankle vascular index in asymptomatic subjects. Wien Klin Wochenschr 128(suppl 8):610–613PubMed Akyuz AR, Turan T, Erkus ME, Gurbak KS et al (2016) Xanthelasma palpebrarum associated with increased cardio-ankle vascular index in asymptomatic subjects. Wien Klin Wochenschr 128(suppl 8):610–613PubMed
24.
Zurück zum Zitat Bhat J, Smith AG (2003) Xanthelasma palpebrarum following allergic contact dermatitis from para-phenylenediamine in a black eyelash-tinting product. Contact Dermat 49(6):311 Bhat J, Smith AG (2003) Xanthelasma palpebrarum following allergic contact dermatitis from para-phenylenediamine in a black eyelash-tinting product. Contact Dermat 49(6):311
25.
Zurück zum Zitat Platsidaki E, Kouris A, Agiasofitou E, Antoniou C, Kontochristopoulos G (2016) Periorbital hyperpigmentation in patients with xanthelasma palpebrarum :an interesting observation. J Clin Aesthet Dermatol 9(4):52–54PubMedPubMedCentral Platsidaki E, Kouris A, Agiasofitou E, Antoniou C, Kontochristopoulos G (2016) Periorbital hyperpigmentation in patients with xanthelasma palpebrarum :an interesting observation. J Clin Aesthet Dermatol 9(4):52–54PubMedPubMedCentral
26.
Zurück zum Zitat D’Acunto C, Pazzaglia M, Raone B, Misciali C, Badiali L, Neri I, Patrizi A (2013) Xanthelasma palpebrarum: a new adverse reaction to intradermal fillers? Br J Dermatol 168(2):437–439PubMed D’Acunto C, Pazzaglia M, Raone B, Misciali C, Badiali L, Neri I, Patrizi A (2013) Xanthelasma palpebrarum: a new adverse reaction to intradermal fillers? Br J Dermatol 168(2):437–439PubMed
27.
Zurück zum Zitat Başterzi Y, Sari A (2006) Xanthelasma palpebrarum after septorhinoplasty. Aesthetic Plast Surg 30(4):492–493PubMed Başterzi Y, Sari A (2006) Xanthelasma palpebrarum after septorhinoplasty. Aesthetic Plast Surg 30(4):492–493PubMed
28.
Zurück zum Zitat Scott PJ, Winterbourn CC (1967) Low-density lipoprotein accumulation in actively growing xanthomas. J Atheroscler Res 7(2):207–223PubMed Scott PJ, Winterbourn CC (1967) Low-density lipoprotein accumulation in actively growing xanthomas. J Atheroscler Res 7(2):207–223PubMed
29.
Zurück zum Zitat Seike M, Ikeda M, Matsumoto M, Hamada R, Takeya M, Kodama H (2006) Hyaluronan forms complexes with low density lipoprotein while also inducing foam cell infiltration in the dermis. J Dermatol Sci 41(3):197–204PubMed Seike M, Ikeda M, Matsumoto M, Hamada R, Takeya M, Kodama H (2006) Hyaluronan forms complexes with low density lipoprotein while also inducing foam cell infiltration in the dermis. J Dermatol Sci 41(3):197–204PubMed
31.
Zurück zum Zitat Karsai S, Czarnecka A, Raulin C (2010) Treatment of xanthelasma palpebrarum using a pulsed dye laser: a prospective clinical trial in 38 cases. Dermatol Surg 36(5):610–617PubMed Karsai S, Czarnecka A, Raulin C (2010) Treatment of xanthelasma palpebrarum using a pulsed dye laser: a prospective clinical trial in 38 cases. Dermatol Surg 36(5):610–617PubMed
32.
Zurück zum Zitat Parkes ML, Waller TS (1984) Xanthelasma palpebrarum. Laryngoscope 94(9):1238–1240PubMed Parkes ML, Waller TS (1984) Xanthelasma palpebrarum. Laryngoscope 94(9):1238–1240PubMed
33.
Zurück zum Zitat Lee HY, Jin US, Minn KW, Park Y-O (2013) Outcomes of surgical management of xanthelasma palpebrarum. Arch Plast Surg 40:380–386PubMedPubMedCentral Lee HY, Jin US, Minn KW, Park Y-O (2013) Outcomes of surgical management of xanthelasma palpebrarum. Arch Plast Surg 40:380–386PubMedPubMedCentral
34.
Zurück zum Zitat Kose R (2013) Treatment of large xanthelasma palpebrarums with full-thickness skin grafts obtained by blepharoplasty. J Cutan Med Surg 17(3):197–200PubMed Kose R (2013) Treatment of large xanthelasma palpebrarums with full-thickness skin grafts obtained by blepharoplasty. J Cutan Med Surg 17(3):197–200PubMed
35.
Zurück zum Zitat Roberts HL (1926) The Chloroacetic acids: a biochemical study. Br J Dermatol 38:323–391 Roberts HL (1926) The Chloroacetic acids: a biochemical study. Br J Dermatol 38:323–391
36.
Zurück zum Zitat Haygood LJ, Bennett JD, Brodell RT (1998) Treatment of xanthelasma palpebrarum with bichloracetic acid. Dermatol Surg 24(9):1027–1031PubMed Haygood LJ, Bennett JD, Brodell RT (1998) Treatment of xanthelasma palpebrarum with bichloracetic acid. Dermatol Surg 24(9):1027–1031PubMed
37.
Zurück zum Zitat Cannon PS, Ajit R, Leatherbarrow B (2010) Efficacy of trichloroacetic acid (95%) in the management of xanthelasma palpebrarum. Clin Exp Dermatol 35(8):845–848PubMed Cannon PS, Ajit R, Leatherbarrow B (2010) Efficacy of trichloroacetic acid (95%) in the management of xanthelasma palpebrarum. Clin Exp Dermatol 35(8):845–848PubMed
38.
Zurück zum Zitat Haque MU, Ramesh V (2006) Evaluation of three different strengths of trichloroacetic acid in xanthelasma palpebrarum. J Dermatol Treat 17(1):48–50 Haque MU, Ramesh V (2006) Evaluation of three different strengths of trichloroacetic acid in xanthelasma palpebrarum. J Dermatol Treat 17(1):48–50
39.
Zurück zum Zitat Nahas TR, Marques JC, Nicoletti A, Cunha M, Nishiwaki-Dantas MC, Filho JV (2009) Treatment of eyelid xanthelasma with 70% trichloroacetic acid. Ophthalmic Plast Reconstr Surg 25(4):280–283PubMed Nahas TR, Marques JC, Nicoletti A, Cunha M, Nishiwaki-Dantas MC, Filho JV (2009) Treatment of eyelid xanthelasma with 70% trichloroacetic acid. Ophthalmic Plast Reconstr Surg 25(4):280–283PubMed
40.
Zurück zum Zitat Dincer D, Koc E, Erbil AH, Kose O (2010) Effectiveness of low-voltage radiofrequency in the treatment of xanthelasma palpebrarum: a pilot study of 15 cases. Dermatol Surg 36(12):1973–1978PubMed Dincer D, Koc E, Erbil AH, Kose O (2010) Effectiveness of low-voltage radiofrequency in the treatment of xanthelasma palpebrarum: a pilot study of 15 cases. Dermatol Surg 36(12):1973–1978PubMed
41.
Zurück zum Zitat Dawber R, Colver G, Jackson A, Pringle F (1992) Cutaneous cryosurgery. Principles and Clinical practice. Martin Dunitz, London Dawber R, Colver G, Jackson A, Pringle F (1992) Cutaneous cryosurgery. Principles and Clinical practice. Martin Dunitz, London
42.
Zurück zum Zitat Kuflik EG, Gage AA (1990) Cryosurgical treatment of skin cancer. Igaku-Shoin, Newyork Kuflik EG, Gage AA (1990) Cryosurgical treatment of skin cancer. Igaku-Shoin, Newyork
43.
Zurück zum Zitat Sheperd J, Dawber RP (1982) The historical and scientific basis of cryosurgery. Clin Exp Dermatol 7:321–328 Sheperd J, Dawber RP (1982) The historical and scientific basis of cryosurgery. Clin Exp Dermatol 7:321–328
44.
Zurück zum Zitat Dewan SP, Kaur A, Gupta RK (1995) Effectiveness of cryosurgery in xanthelasma palpebrarum. Indian J Dermatol Venereol Leprol 61(1):4–7PubMed Dewan SP, Kaur A, Gupta RK (1995) Effectiveness of cryosurgery in xanthelasma palpebrarum. Indian J Dermatol Venereol Leprol 61(1):4–7PubMed
45.
Zurück zum Zitat Labandeira J, Vázquez-Osorio I, Figueroa-Silva O, Pereiro M Jr, Toribio J (2015) Tolerability and effectiveness of liquid nitrogen spray cryotherapy with very short freeze times in the treatment of xanthelasma palpebrarum. Dermatol Ther 28(6):346–350PubMed Labandeira J, Vázquez-Osorio I, Figueroa-Silva O, Pereiro M Jr, Toribio J (2015) Tolerability and effectiveness of liquid nitrogen spray cryotherapy with very short freeze times in the treatment of xanthelasma palpebrarum. Dermatol Ther 28(6):346–350PubMed
46.
Zurück zum Zitat Delgado Navarro C, Lanuza García A, Llorca Cardeñosa A, Bañón-Navarro R, Corchero MG (2013) Application of laser CO2 for the treatment of xanthelasma palpebrarum. Arch Soc Esp Oftalmol 88:320–322PubMed Delgado Navarro C, Lanuza García A, Llorca Cardeñosa A, Bañón-Navarro R, Corchero MG (2013) Application of laser CO2 for the treatment of xanthelasma palpebrarum. Arch Soc Esp Oftalmol 88:320–322PubMed
47.
Zurück zum Zitat Raulin C, Schoenermark MP, Werner S, Greve B (1999) Xanthelasma palpebrarum: treatment with the ultrapulsed CO2 laser. Lasers Surg Med 24(2):122–127PubMed Raulin C, Schoenermark MP, Werner S, Greve B (1999) Xanthelasma palpebrarum: treatment with the ultrapulsed CO2 laser. Lasers Surg Med 24(2):122–127PubMed
48.
Zurück zum Zitat Pathania V, Chatterjee M (2015) Ultrapulse carbon dioxide laser ablation of xanthelasma palpebrarum: a case series. J Cutan Aesthet Surg 8(1):46–49PubMedPubMedCentral Pathania V, Chatterjee M (2015) Ultrapulse carbon dioxide laser ablation of xanthelasma palpebrarum: a case series. J Cutan Aesthet Surg 8(1):46–49PubMedPubMedCentral
49.
Zurück zum Zitat Saif MYS (2007) Xanthelasma palpebrarum treatment by CO2 laser. Bull Ophthalmol Soc Egypt 100:791–794 Saif MYS (2007) Xanthelasma palpebrarum treatment by CO2 laser. Bull Ophthalmol Soc Egypt 100:791–794
50.
Zurück zum Zitat Esmat SM, Elramly AZ, Abdel Halim DM, Gawdat HI, Taha HI (2014) Fractional CO2 laser is an effective therapeutic modality of xanthelasma palpebrarum: a randomized clinical trial. Dermatol Surg 40(20):1349–1355PubMed Esmat SM, Elramly AZ, Abdel Halim DM, Gawdat HI, Taha HI (2014) Fractional CO2 laser is an effective therapeutic modality of xanthelasma palpebrarum: a randomized clinical trial. Dermatol Surg 40(20):1349–1355PubMed
51.
Zurück zum Zitat Borelli C, Kaudewitz P (2001) Xanthelasma palpebrarum: treatment with the erbium:YAG laser. Lasers Surg Med 29(3):260–264PubMed Borelli C, Kaudewitz P (2001) Xanthelasma palpebrarum: treatment with the erbium:YAG laser. Lasers Surg Med 29(3):260–264PubMed
52.
Zurück zum Zitat Mannino G, Papale A, De Bella F, Mollo R (2001) Use of Erbium:YAG laser in the treatment of palpepral xanthelasmas. Opthalmic Surg Lasers 32:129–133 Mannino G, Papale A, De Bella F, Mollo R (2001) Use of Erbium:YAG laser in the treatment of palpepral xanthelasmas. Opthalmic Surg Lasers 32:129–133
53.
Zurück zum Zitat Kaufmann R, Hibst R (1996) Pulsed Erbium-YAG laser ablation in cutaneous surgery. Lasers Surg Med 19:324–330PubMed Kaufmann R, Hibst R (1996) Pulsed Erbium-YAG laser ablation in cutaneous surgery. Lasers Surg Med 19:324–330PubMed
54.
Zurück zum Zitat Drnovsek-Olup B, Vedlin B (1997) Use of Erbium:YAG laser for benign skin disorders. Lasers Surg Ned 21:13–19 Drnovsek-Olup B, Vedlin B (1997) Use of Erbium:YAG laser for benign skin disorders. Lasers Surg Ned 21:13–19
55.
Zurück zum Zitat Levy JL, Trelles MA (2003) New operative technique for treatment of xanthelasma palpebrarum: laser-inverted resurfacing: preliminary report. Ann Plast Surg 50(4):339–343PubMed Levy JL, Trelles MA (2003) New operative technique for treatment of xanthelasma palpebrarum: laser-inverted resurfacing: preliminary report. Ann Plast Surg 50(4):339–343PubMed
56.
Zurück zum Zitat Anderson RR, Margolis RJ, Watenabe S, Flotte T, Hruza GJ, Dover JS (1989) Selective photothermolysis of cutaneous pigmentation by Q-switched Nd: YAG laser pulses at 1064, 532, and 355 nm. J Invest Dermatol 93(1):28–32PubMed Anderson RR, Margolis RJ, Watenabe S, Flotte T, Hruza GJ, Dover JS (1989) Selective photothermolysis of cutaneous pigmentation by Q-switched Nd: YAG laser pulses at 1064, 532, and 355 nm. J Invest Dermatol 93(1):28–32PubMed
57.
Zurück zum Zitat Fusade T (2008) Treatment of xanthelasma palpebrarum by 1064-nm Q-switched Nd: YAG laser: a study of 11 cases. Br J Dermatol 158(1):84–87PubMed Fusade T (2008) Treatment of xanthelasma palpebrarum by 1064-nm Q-switched Nd: YAG laser: a study of 11 cases. Br J Dermatol 158(1):84–87PubMed
58.
Zurück zum Zitat Karsai S, Schmitt L, Raulin C (2009) Is Q-switched neodymium-doped yttrium aluminium garnet laser an effective approach to treat xanthelasma palpebrarum? Results from a clinical study of 76 cases. Dermatol Surg 35(12):1962–1969PubMed Karsai S, Schmitt L, Raulin C (2009) Is Q-switched neodymium-doped yttrium aluminium garnet laser an effective approach to treat xanthelasma palpebrarum? Results from a clinical study of 76 cases. Dermatol Surg 35(12):1962–1969PubMed
59.
Zurück zum Zitat Marini L (2013) 1064 nm Q-switched photo-acoustic laser ablation of xanthelasma palpebrarum. J Laser Health Acad 1:48–51 Marini L (2013) 1064 nm Q-switched photo-acoustic laser ablation of xanthelasma palpebrarum. J Laser Health Acad 1:48–51
60.
Zurück zum Zitat Berger C, Kopera D (2005) KTP laser coagulation for xanthelasma palpebrarum. J Dtsch Dermatol 3(10):775–779 Berger C, Kopera D (2005) KTP laser coagulation for xanthelasma palpebrarum. J Dtsch Dermatol 3(10):775–779
61.
Zurück zum Zitat Greijmans E, Luiting-Welkenhuyzen H, Luijks H, Bovenschen HJ (2016) Continuous wave potassium titanyl phosphate laser treatment is safe and effective for xanthelasma palpebrarum. Dermatol Surg 42(7):860–866PubMed Greijmans E, Luiting-Welkenhuyzen H, Luijks H, Bovenschen HJ (2016) Continuous wave potassium titanyl phosphate laser treatment is safe and effective for xanthelasma palpebrarum. Dermatol Surg 42(7):860–866PubMed
62.
Zurück zum Zitat Schönermark MP, Raulin C (1996) Treatment of xanthelasma palpebrarum with the pulsed dye laser. Lasers Surg Med 19(3):336–339PubMed Schönermark MP, Raulin C (1996) Treatment of xanthelasma palpebrarum with the pulsed dye laser. Lasers Surg Med 19(3):336–339PubMed
63.
Zurück zum Zitat Astner S (2009) Clinical applicability of a 1 450 nm diode laser as adjunctive treatment for refractory acne. G Ital Dermatol Venereol 144(6):629–638PubMed Astner S (2009) Clinical applicability of a 1 450 nm diode laser as adjunctive treatment for refractory acne. G Ital Dermatol Venereol 144(6):629–638PubMed
64.
Zurück zum Zitat Friedman PM, Jih MH, Kimyai-Asadi A, Goldberg LH (2004) Treatment of inflammatory facial acne vulgaris with the 1450-nm diode laser: a pilot study. Dermatol Surg 30(2 Pt 1):147–151PubMed Friedman PM, Jih MH, Kimyai-Asadi A, Goldberg LH (2004) Treatment of inflammatory facial acne vulgaris with the 1450-nm diode laser: a pilot study. Dermatol Surg 30(2 Pt 1):147–151PubMed
65.
Zurück zum Zitat No D, McClaren M, Chotzen V, Kilmer SL (2004) Sebaceous hyperplasia treated with a 1450-nm diode laser. Dermatol Surg 30(3):382–384PubMed No D, McClaren M, Chotzen V, Kilmer SL (2004) Sebaceous hyperplasia treated with a 1450-nm diode laser. Dermatol Surg 30(3):382–384PubMed
66.
Zurück zum Zitat Chua SH, Ang P, Khoo LS, Goh CL (2004) Nonablative 1450-nm diode laser in the treatment of facial atrophic acne scars in type IV to V Asian skin: a prospective clinical study. Dermatol Surg 30(10):1287–1291PubMed Chua SH, Ang P, Khoo LS, Goh CL (2004) Nonablative 1450-nm diode laser in the treatment of facial atrophic acne scars in type IV to V Asian skin: a prospective clinical study. Dermatol Surg 30(10):1287–1291PubMed
67.
Zurück zum Zitat Park EJ, Youn SH, Cho EB, Lee GS, Hann SK, Kim KH, Kim KJ (2011) Xanthelasma palpebrarum treatment with a 1450-nm-diode laser. Dermatol Surg 37(6):791–796PubMed Park EJ, Youn SH, Cho EB, Lee GS, Hann SK, Kim KH, Kim KJ (2011) Xanthelasma palpebrarum treatment with a 1450-nm-diode laser. Dermatol Surg 37(6):791–796PubMed
68.
Zurück zum Zitat Shields CL, Mashayekhi A, Shields JA (2005) Disappearance of eyelid xanthelasma following oral simvastatin (Zocor). Br J Ophthalmol 89:639–645PubMedPubMedCentral Shields CL, Mashayekhi A, Shields JA (2005) Disappearance of eyelid xanthelasma following oral simvastatin (Zocor). Br J Ophthalmol 89:639–645PubMedPubMedCentral
69.
Zurück zum Zitat Wang H, Shi Y, Guan H, Liu C, Zhang W et al (2016) Treatment of xanthelasma palpebrarum with intralesional pingyangmycin. Dermatol Surg 42(3):368–376PubMed Wang H, Shi Y, Guan H, Liu C, Zhang W et al (2016) Treatment of xanthelasma palpebrarum with intralesional pingyangmycin. Dermatol Surg 42(3):368–376PubMed
70.
Zurück zum Zitat Mourad B, Elgarhy LH, Ellakkawy HA, Elmahdy N (2015) Assessment of efficacy and tolerability of different concentrations of trichloroacetic acid vs. carbon dioxide laser in treatment of xanthelasma palpebrarum. J CosmetDermatol 14(3):209–215 Mourad B, Elgarhy LH, Ellakkawy HA, Elmahdy N (2015) Assessment of efficacy and tolerability of different concentrations of trichloroacetic acid vs. carbon dioxide laser in treatment of xanthelasma palpebrarum. J CosmetDermatol 14(3):209–215
71.
Zurück zum Zitat Goel K, Sardana K, Garg VK (2015) A prospective study comparing ultrapulse CO2 laser and trichloroacetic acid in treatment of Xanthelasmapalpebrarum. J Cosmet Dermatol 14(2):130–139PubMed Goel K, Sardana K, Garg VK (2015) A prospective study comparing ultrapulse CO2 laser and trichloroacetic acid in treatment of Xanthelasmapalpebrarum. J Cosmet Dermatol 14(2):130–139PubMed
72.
Zurück zum Zitat Abdelkader M, Alashry SE (2015) Argon laser versus erbium:YAG laser in the treatment of xanthelasma palpebrarum. Saudi J Ophthalmol 29(2):116–120PubMed Abdelkader M, Alashry SE (2015) Argon laser versus erbium:YAG laser in the treatment of xanthelasma palpebrarum. Saudi J Ophthalmol 29(2):116–120PubMed
73.
Zurück zum Zitat Güngör S, Canat D, Gökdemir G (2014) Erbium:YAG laser ablation versus 70% trichloroacetıc acid application in the treatment of xanthelasma palpebrarum. J Dermatol Treat 25(4):290–293 Güngör S, Canat D, Gökdemir G (2014) Erbium:YAG laser ablation versus 70% trichloroacetıc acid application in the treatment of xanthelasma palpebrarum. J Dermatol Treat 25(4):290–293
Metadaten
Titel
Xanthelasma Palpebrarum: More than Meets the Eye
verfasst von
Shailesh Khode
Soon Heng Terry Tan
En-Pei Amanda Tan
Sandeep Uppal
Publikationsdatum
07.04.2018
Verlag
Springer India
Erschienen in
Indian Journal of Otolaryngology and Head & Neck Surgery / Ausgabe Sonderheft 1/2019
Print ISSN: 2231-3796
Elektronische ISSN: 0973-7707
DOI
https://doi.org/10.1007/s12070-018-1345-0

Weitere Artikel der Sonderheft 1/2019

Indian Journal of Otolaryngology and Head & Neck Surgery 1/2019 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

HNO-Op. auch mit über 90?

16.04.2024 HNO-Chirurgie Nachrichten

Mit Blick auf das Risiko für Komplikationen nach elektiven Eingriffen im HNO-Bereich scheint das Alter der Patienten kein ausschlaggebender Faktor zu sein. Entscheidend ist offenbar, wie fit die Betroffenen tatsächlich sind.

Intrakapsuläre Tonsillektomie gewinnt an Boden

16.04.2024 Tonsillektomie Nachrichten

Gegenüber der vollständigen Entfernung der Gaumenmandeln hat die intrakapsuläre Tonsillektomie einige Vorteile, wie HNO-Fachleute aus den USA hervorheben. Sie haben die aktuelle Literatur zu dem Verfahren gesichtet.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.